March 21, 2024
StemRIM Inc.

StemRIM Announces Symposium on "Regeneration-Inducing Medicine™" at the 23rd Congress of the Japanese Society for Regenerative Medicine

Osaka, Japan, March 21, 2024 – StemRIM Inc. (TSE: 4599, President and CEO: Masatsune Okajima; “StemRIM”) announces that a symposium on the research findings regarding our "Regeneration-Inducing Medicine™", developed by our company, will be held at the 23rd Congress of the Japanese Society for Regenerative Medicine from March 21st to 23rd, 2024. For further details, please refer to the information below.

Date and Time: March 22, 2024 (Friday) 15:40-17:40

Session: SY-19 Development of Tissue "Regeneration-Inducing Medicine™" Through Niche Environment Control

Chairpersons:
Katsuto Tamai, *StemRIM Inc. / Osaka University Graduate School of Medicine*
Yasuhiko Tabata, *Department of Biomaterials, Field of Tissue Engineering, Institute for Frontier Medical Sciences, Kyoto University*

Presentation:

SY-19-1 Design Technology of Niche Environment to Naturally Induce Tissue Regenerative Therapy
Yasuhiko Tabata, *Department of Biomaterials, Field of Tissue Engineering, Institute for Frontier Medical Sciences, Kyoto University*

SY-19-2 Phase II physician-initiated clinical trial in patients with chronic liver disease to evaluate the effect of S-005151 on Fibrosis Improvement
Tsuchiya Atsunori, *Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University*

SY-19-3 Regeneration-inducible medicine for bone resorptive disease by utilizing intricate crosstalk between bone-destroying osteoclasts and bone-reforming osteoblasts
Masaru Ishi, *Department of Immunology and Cell Biology, Osaka University Graduate School of Medicine*

SY-19-4 The development of new strategy in tissue regeneration by Control of stem cell niche environment and stem cell recruitment inducers
Shigeru Miyagawa, *Department of Cardiovascular Surgery Osaka University Graduate School of Medicine*

SY-19-5 Mechanism inducing epidermal stem cell regeneration by ectodermal mesenchymal cells
Katsuto Tamai, *StemRIM Inc. / Osaka University Graduate School of Medicine*

About StemRIM Inc.

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called "Regeneration-Inducing Medicine™". The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely

through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. "Regeneration-Inducing Medicine™" is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration. Certain disease areas expected to benefit from "Regeneration-Inducing Medicine™" include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH), systemic sclerosis, and any other areas where treatment with extrapulmonary mesenchymal stem cells is promising.

Inquiries:

StemRIM Inc.
Management & Administrator Dept.
E-Mail: stemrim-ir@stemrim.com
Twitter: @StemRIM_Inc

For more information, please visit the StemRIM website (https://stemrim.com/english/)